cook and gsk, page-11

I think it is slightly unfair to solely blame PC for the GSK affair, as that would have been a board decision and he is but one person on that board. Yes he should have turned down his options at the 2008 AGM, but similarly the board should have asked him to do so.

It is interesting to note that Gilead, primarily on the back of Tamiflu, has gone on to be $31B company with their 20% Tamiflu royalty now only representing 7% of their revenue. Thats shows what good management and a little luck can do.

For those interested in US stocks, GILD is currently cheap and amoung my top picks in biotech. Forward P/E of 8.5 and PEG of 0.63. Strong BS and throwing off a lot of cash.

No position in GILD, but looking very closely.

Here's a question for all.
Dr Leigh Farrell was appointed Vice President, Business Development on 24 April 2006. What deals has Dr Farrell done in the last 4.8 years?
RSV deal was done before his time, IIRC it was 2005, and I can't recall any deals done since. Certainly none since I became a shareholder in 2008.